Compare ATHM & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATHM | AUPH |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2013 | 2014 |
| Metric | ATHM | AUPH |
|---|---|---|
| Price | $17.78 | $15.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $28.00 | $17.25 |
| AVG Volume (30 Days) | 710.2K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.83% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | N/A | $17.54 |
| Revenue Next Year | $4.77 | $15.74 |
| P/E Ratio | ★ $12.13 | $63.40 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $15.57 | $7.29 |
| 52 Week High | $29.92 | $16.88 |
| Indicator | ATHM | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 51.59 | 52.74 |
| Support Level | $16.22 | $14.60 |
| Resistance Level | $18.81 | $16.38 |
| Average True Range (ATR) | 0.83 | 0.54 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 72.84 | 50.43 |
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent, and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead-generation service provider in China's online auto platform media advertising market, in terms of media services and lead-generation revenue.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.